Document is current
Any future updates will be listed below
-
Authors
Sartore-Bianchi, Andrea https://orcid.org/0000-0003-0780-0409
Pietrantonio, Filippo https://orcid.org/0000-0002-8530-8420
Lonardi, Sara https://orcid.org/0000-0002-7593-8138
Mussolin, Benedetta
Rua, Francesco
Crisafulli, Giovanni https://orcid.org/0000-0002-5511-1555
Bartolini, Alice
Fenocchio, Elisabetta https://orcid.org/0000-0001-6679-0955
Amatu, Alessio https://orcid.org/0000-0001-5396-3378
Manca, Paolo
Bergamo, Francesca
Tosi, Federica
Mauri, Gianluca https://orcid.org/0000-0002-7646-0973
Ambrosini, Margherita https://orcid.org/0000-0003-4131-2409
Daniel, Francesca
Torri, Valter
Vanzulli, Angelo
Regge, Daniele
Cappello, Giovanni
Marchiò, Caterina
Berrino, Enrico https://orcid.org/0000-0001-6728-5619
Sapino, Anna https://orcid.org/0000-0003-3542-9571
Marsoni, Silvia
Siena, Salvatore https://orcid.org/0000-0002-2681-2846
Bardelli, Alberto https://orcid.org/0000-0003-1647-5070
- License Information
-
More Information
Article History
Received: 24 December 2021
Accepted: 1 June 2022
First Online: 1 August 2022
Competing interests
: A.S.-B. is an advisory board member for Amgen, Bayer, Novartis, Sanofi and Servier. F.P. received honoraria/speaker activity from Merck Serono, Amgen, Sanofi, Eli Lilly, Bayer, Servier, AstraZeneca, Merck Sharp & Dohme and Organon and received research grants from Bristol-Myers Squibb and AstraZeneca. S.L. is an advisory board member for Amgen, Merck Serono, Eli Lilly, AstraZeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier and Merck Sharp & Dohme and participated in Speakers’ Bureau for Roche, Eli Lilly, Bristol-Myers Squibb, Servier, Merck Serono, Pierre-Fabre, GlaxoSmithKline and Amgen and received research funding from Amgen, Merck Serono, Bayer, Roche, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. A.A. is an advisory board member for Roche and Bayer and received honoraria from CheckmAb. C.M. received personal consultancy fees from Bayer, Roche, Daiichi-Sankyo and AstraZeneca. S.S. is an advisory board member for Agenus, AstraZeneca, Bayer, Bristol-Myers Squibb, CheckmAb, Daiichi-Sankyo, Guardant Health, Menarini, Merck, Novartis, Roche-Genentech and Seagen. A.B. is an advisory board member for NeoPhore and Inivata and a shareholder of NeoPhore and received research support from AstraZeneca and Boehringer Ingelheim. The remaining authors declare no competing interests.
